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It has been shown that human CD4 expressed in nonhuman cells does not support HIV-1 entry into those cells and that
components from human cells in addition to CD4 are required to overcome the block. We have used human red blood cells
(huRBC) as a source for the accessory components since their membrane composition is less complex than that of nucleated
cells and they are well characterized. Components were transferred by fusion of huRBC to nonhuman CD4/ cells mediated
by influenza hemagglutinin or polyethylene glycol. The RBC-modified nonhuman CD4/ cells were labeled with fluorescent
markers and incubated with gp120 –gp41-expressing cells labeled with a different fluorescent probe. Fusion between RBC-
modified nonhuman CD4/ cells and gp120– gp41-expressing cells was quantified by fluorescence video microscopy. Human
erythrocyte components transferred to nonhuman CD4/ cells conferred HIV-1 envelope glycoprotein-mediated fusion sus-
ceptibility to those cells. The fusion was enhanced by pretreatment of the erythrocytes for 10 min at 567. No gp120 – gp41-
mediated fusion was observed when components from nonhuman RBC were transferred to nonhuman CD4/ cells. Human
cell lines with pre-RBC characteristics (K562-CD4) also supported HIV-1 envelope glycoprotein-mediated fusion. q 1996
Academic Press, Inc.
Human immunodeficiency virus type-1 (HIV-1)3 enters gp120 – gp41 (1, 13, 20– 22). On the other hand the major-
permissive cells by binding to its cellular receptor CD4 ity of human cell lines become permissive to HIV-1 enve-
(1– 11). The interaction between HIV-1 envelope glyco- lope glycoprotein-mediated fusion and/or to HIV-1 entry
protein (gp120– gp41) and CD4 leads to conformational provided that human CD4 is expressed on their surface
changes in gp120 – gp41 which allows fusion between (15, 16). This block has been shown to be at the mem-
viral and target membranes (5, 9, 10). It is well estab- brane fusion level and can be overcome by transfer of
lished that HIV-1 fusion requires the participation of addi- human cellular factors into nonhuman cells (15 – 23). Al-
tional, not yet identified, cellular components in the target though a number of cellular factors have been proposed
membrane (12 – 16, 19). These additional factors are spe- as putative accessory factors for HIV-1 entry or cell fusion
cific to the human cells since the expression of human (for reviews see Refs. 9– 11) none of these molecules are
CD4 in nonhuman cell lines supports neither their infec- sufficient or absolutely required for HIV-1 entry. Recently
tion by HIV-1 nor their fusion with cells expressing Dragic et al. (17) have shown that proteinase-resistant
factors in huRBC membranes can confer the CD4-depen-
dent fusion activity. They also reported that human cell
1 Current address: CSB 1947, Williamsburg, VA 23186. lines with pre-RBC characteristics (K562-CD4) do not2 To whom reprint requests should be addressed. Fax: (301) 402-
support gp120 – gp41-mediated fusion (17).3650; E-mail: blumen@helix.nih.gov.
3 Abbreviations used: HIV-1, human immunodeficiency virus type 1; Here we present a novel quantitative fluorescence mi-
huRBC, human red blood cells; HA, influenza hemagglutinin; PEG, poly- croscopic cell – cell fusion assay to study the nature of
ethylene glycol; DMEM, Dulbecco’s modified Eagle’s medium supple- accessory components required for HIV-1 envelope gly-
mented with 10% heat-inactivated fetal bovine serum, 100 units/ml peni-
coprotein-mediated fusion. The assay is based on thecillin, 100 mg/ml streptomycin; RPMI, RPMI-1640 supplemented with
redistribution of fluorescent probes between effector and10% fetal bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin;
PBS, phosphate-buffered saline containing 137 mM NaCl, 2.7 mM KCl, target cells upon fusion. Although fluorescent dye combi-
8.1 mM Na2HPO4 , 1.5 mM KH2PO4 , pH 7.4; R18, octadecylrhodamine; nations have been used to monitor fusion between cells
PK, proteinase K; CMTMR, 5-(and 6)-([(4-chloromethyl)benzoyl]- (18), to our knowledge the quantitation of cell – cell fusionamino)tetramethylrhodamine; CMFDA, 5-chloromethylfluorescein diac-
based on the overlap of fluorescent markers has notetate; DiI, 1,1*-dioctadecyl-3,3,3*,3*-tetramethylindocarbocyanine per-
chlorate. been described to date. Application of two probes can
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be useful to monitor lipid vs cytosolic mixing for a given (described below). In parallel experiments unlabeled
RBC were fused with mink-CD4 cells using the samefusion event in the same cell population. To transfer hu-
man membrane components more efficiently, we use in- protocol and the cells were loaded with CMTMR (see
below). There was no difference in the complementationfluenza hemagglutinin (HA) to induce fusion between
RBC and nonhuman CD4/ cells. We report here that the efficiency for HIV-1 envelope glycoprotein-mediated fu-
sion whether R18-labeled or unlabeled RBC were used.accessory molecules in human erythrocyte membranes
are insensitive to heat treatment at 567 for 10 min. We We have also used a mouse 3T3 fibroblast cell line, GP4F
(25) (a kind gift from Judith White) which constitutivelyalso report that K562-CD4 cells serve as suitable targets
for gp120 – gp41-mediated cell –cell fusion. expresses influenza hemagglutinin (A/Japan/305/57). To
express human CD4 we used a vaccinia recombinantAll fluorescent probes used in this study were obtained
from Molecular Probes (Eugene, OR) and culture media vCB3 which encodes the gene for full-length human CD4
(a kind gift from C. C. Broder and E. A. Berger, NIAID,were from Gibco BRL (Life Technologies, Gaithersburg,
MD). Mink lung (Mv-l-lu) cells expressing human CD4 Bethesda, MD) (15). GP4F cells were infected with vCB3
at m.o.i. of 10 at 377 for 3– 4 hr, R18 RBC were bound to(mink-CD4, a kind gift from Dr. Paul Clapham, Chester
Beatty Institute, London) were grown in DMEM supple- CD4-expressing GP4F cells, and fusion was triggered at
low pH as described above. PEG-induced fusion be-mented with 5% heat-inactivated fetal bovine serum (FBS)
and G418 (1 mg/ml) (20). To express HA on the cell tween RBC and CD4/ nonhuman cells was performed
according to Dragic et al. (17) except that the two cellsurface, mink-CD4 cells (105 plated on microwells, 14-
mm coverslips No. 0; MatTek Corp., Asland, MA) were types were preaggregated with 5% PEG. Although we did
not quantify the efficiency of PEG-mediated RBC – minkinfected with PR/8 influenza virus (A/PR8/34/H1N1) (24)
for 5 hr at 377. Human blood was obtained from NIH fusion our general impression was that most of the mink-
CD4 cells became stained with lipid dye following theblood bank (Bethesda, MD). Nonhuman blood was ob-
tained from Truslow Farms (Chestertown, MD), Rockland, PEG treatment. However, complementation efficiency for
HIV-1 envelope glycoprotein-mediated fusion was veryInc. (Gilbertsville, PA), and Pel-Freez Biologicals (Rogers,
AR). Whole blood was washed three times with PBS and low following the PEG treatment of huRBC– mink-CD4
cells. The lack of correlation between the PEG-inducedthe buffy coat was discarded. HA-mediated RBC – mink-
CD4 cell fusion was performed as described (24 – 26). RBC – mink-CD4 fusion and subsequent fusion with
TF228 cells might be due to the fact that the target cellsBriefly, erythrocytes from human or nonhuman sources
were labeled with a lipid probe octadecylrhodamine became somewhat impaired for HIV-1 fusion following
the PEG treatment.(R18) (25) and kept at 47 until further use. Since HA is
expressed on the cell surface as a fusion-inactive precur- CD4-expressing cells (after the transfer of human com-
ponents, as described above) were loaded with 10 mMsor (HA0), the cells were treated with 5 mg/ml trypsin for
5 min at room temperature to convert HA0 to HA. R18- CMTMR [5-(and-6)-([(4-chloromethyl)benzoyl]amino)-tet-
ramethylrhodamine, ex/em 541/565 nm] in DMEM for 30–labeled RBC were allowed to bind to HA-expressing cells
for 20 min at room temperature (24). Fusion between 60 min at 377. CMTMR reacts with intracellular free sulf-
hydryls, predominantly glutathione. The dye solution wasmink-CD4 and RBC was induced by brief exposure (60
sec) of the cells to pH 5.1 followed by incubation in replaced with fresh medium and the cells were further
incubated for at least 30 min at 377. A human lymphoidculture medium at pH 7.4 for 30 min at 377. We assessed
how many RBC bound to mink-CD4 cells and how many cell line which stably expresses HIV-1 envelope glyco-
protein, TF228.1.16 (27) (a kind gift from Zdenka L. Jonak,CD4/ cells were stained with R18 following the low-pH
treatment by microscopy. We found that 100% of the Smithkline Beecham Pharmaceuticals, PA), was main-
tained in suspension culture using RPMI (RPMI 1640mink-CD4 cells that had at least one bound huRBC were
stained with the lipid dye following low-pH treatment in supplemented with 10% heat inactivated FBS). TF228
cells were incubated with 0.5 mM calcein-AM (ex/em 496/accordance with Schoch and Blumenthal (28). To ascer-
tain specificity of R18 transfer by HA fusion we performed 517 nm) for 60 min at 377 and subsequently washed
to remove excess probe. Fluorescently labeled gp120 –the following controls: (a) HA0 was not cleaved with tryp-
sin but the samples were treated at pH 5.1 as above or gp41-expressing cells and CD4/ cells (at 5:1 ratio, re-
spectively) were cocultured at 377 for 4– 6 hr. At the end(b) HA0 was cleaved with trypsin as described above but
cells were not exposed to pH 5.1. Both controls did not of incubations, bright-field and fluorescent images were
acquired using a 401 fluor oil immersion lens (NA 1.30)show any transfer of R18 from RBC to mink-CD4 cells.
We tested avian, porcine, rabbit, cat, dog, sheep, guinea in a Nikon Diaphot microscope coupled to a Videoscope
image intensifier. An 82000 filter set (Chroma Technologypig, and bovine RBC for their ability to fuse with HA-
expressing nonhuman cells. Goose and guinea pig RBC Corp., Brattleboro, VT) was used for image acquisition
which allowed observation of emission at both the FITCwhich showed HA-mediated fusion efficiencies similar
to that of huRBC were used as negative controls in sub- and the rhodamine wavelengths without changing filter
cubes. The fluorescein and rhodamine excitations weresequent fusion recovery experiments with TF228 cells
AID VY 7846 / 6a14$$$482 04-04-96 15:25:49 vira AP: Virology
264 SHORT COMMUNICATION
switched using a Lambda 10 filter wheel (Sutter Instru- ferred to mink-CD4 cells, a number of cells in the field
became positive for both fluorescent probes (Fig. 1D,ments, Novato, CA) containing FITC and rhodamine exci-
tation filters. To eliminate spillover from the fluorescein indicated by orange yellow color). On the other hand
there was no overlap of dyes in the absence of humanexcitation into the rhodamine emission, a short pass filter
with 560 cutoff was mounted on a slider in the emitted component transfer, when cells were cocultured under
similar conditions (Fig. 1H). The huRBC-modified minklight path. After collection of 6– 10 different fields for each
sample, data were analyzed by overlaying the images cells (lacking CD4) did not confer HIV-1 fusion suscepti-
bility (data not shown) indicating CD4-dependent recov-using Metamorph software (Universal Imaging Corp.,
West Chester, PA). The total number of cells positive for ery of HIV-1 fusion.
To further analyze the nature of the accessory mole-CMTMR or calcein or both dyes were scored. Bright-field
images were used to eliminate false positives where cules, we preincubated huRBC at 567 for 10 min before
fusion with mink-CD4 cells. This treatment is known tolabeled cells were lying over one another but had not
actually fused. Percentage of fusion is calculated as: disrupt cytoskeletal elements and is likely to inactivate
thermally unstable proteins. The results are summarized
in Table 1.% fusion  100 1 (number of cells positive
We found that prior treatment of RBC at 567 did not
for both dyes)/(number of cells
inhibit the recovery of fusion. HIV-1 fusion was specific as
the transfer of components from nonhuman RBC underpositive for CMTMR)
similar conditions did not confer HIV-1 fusion susceptibil-
ity (Table 1). Fusion between TF228 and huRBC modifiedK562, K562-CD4 (a kind gift from Dr. David Klatzmann,
CHU Pitie, Paris), CEM, and TF228 cells were grown in nonhuman CD4/ cells was also inhibited in the presence
of a neutralizing monoclonal antibody OKT4A as wellRPMI medium except that the medium for K562-CD4 cells
also contained 300 mg/ml hygromycin. TF228 cells were as anti-CD4 antiserum (not shown). We performed initial
studies to determine the number of fused huRBC re-incubated for 15 min at room temperature in 12.8 mM DiI
(1,1*-dioctadecyl-3,3,3*,3*-tetramethylindocarbocyanine quired for complementation of HIV-1 envelope glycopro-
tein-mediated fusion. We found substantial increase inperchlorate, ex/em 560/590 nm) in 1:1 RPMI:Diluent C
(Sigma Chemical Co., St. Louis, MO) and washed. K562- complementation efficiency when the number of fused
huRBC was 4. In our experiments we adjusted theCD4, K562, and CEM were labeled with 5 mM CMFDA
(5-chloromethylfluorescein diacetate, ex/em 490/520 nm) concentration of RBC such that on average 3– 8 RBC
were initially bound per mink-CD4 cell. Our remarkableusing conditions similar to labeling with CMTMR as de-
scribed above. CMFDA-loaded cells were resuspended env-mediated fusion efficiencies (approx 20%), compared
with those reported by Dragic et al. (17) (approx 0.01%),in serum-free RPMI and plated on polylysine-coated cov-
erslips. After allowing the cells to attach, serum-free might be due to the deleterious effect of PEG treatment
on the target cells.RPMI was replaced with RPMI medium, and the cells
were cocultured for 2 hr with DiI-labeled TF228 cells 377. To rule out any possible contributions of influenza virus
infection to HIV-1 fusion recovery, we tested our experi-Images were acquired as described above. Since the
target cells were adherent, only TF228 cells in contact mental system using a mouse fibroblast cell line (GP4F)
which constitutively expresses influenza hemagglutinin.with one or more target cells were counted and percent-
age of fusion was calculated as above. We expressed human CD4 by infecting GP4F cells with
vCB3 as described above. The results from these experi-Recovery of HIV-1 envelope glycoprotein-mediated fu-
sion after the transfer of components from human eryth- ments are shown in Fig. 2. We found that fusion between
CD4-expressing GP4F cells and TF228 cells occurredrocyte membranes to mink-CD4 cells is shown in Fig. 1.
When huRBC components were transferred to mink-CD4 only when huRBC were transferred (Figs. 2A – 2D).
HuRBC-modified HA-expressing mouse fibroblasts lack-cells using HA, the resulting huRBC –mink-CD4 cells be-
came susceptible to fusion with gp120 – gp41-expressing ing human CD4 did not confer HIV-1 envelope glycopro-
tein-mediated fusion susceptibility (Fig. 2E). Transfer ofcells. Transfer of components from R18-labeled or unla-
beled huRBC gave similar recoveries of fusion. Transfer components from huRBC ghosts (not shown) or protein-
ase K-treated huRBC to nonhuman CD4/ cells also re-of nonhuman RBC (unlabeled or R18-labeled) under simi-
lar conditions did not mediate recovery of fusion with sulted in the recovery of HIV-1 fusion (Fig. 2C) which
is consistent with the published results (17). Since theTF228 cells. CMTMR-labeled mink-CD4 cells were cocul-
tured with calcein-labeled TF228 cells for 4 hr for 377. At pretreatment of huRBC with proteinase K (PK) abolished
HA-mediated binding to GP4F cells, we added wheatthe end of incubations bright-field (Figs. 1A and 1E) and
fluorescent images were captured using fluorescein germ lectin (WGA) to promote binding between PK-
treated RBC and GP4F cells. To rule out any possible(Figs. 1B and 1F) and rhodamine (Figs. 1C and 1G) wave-
lengths. Figures 1D and 1H show overlays of the fluores- artifacts induced by WGA, we cocultured huRBC – GP4F-
CD4/ cells and TF228 cells with or without WGA. As cancein and rhodamine images. When huRBC were trans-
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FIG. 1. Mink-CD4 cells were infected with influenza virus for 4– 5 hr at 377 and cell-surface-expressed HA was activated by trypsin neuraminidase.
HuRBC were bound, and fusion between RBC and mink-CD4 cells was triggered at pH 5.1 (60 sec). Subsequently cells were loaded with fluorescent
probes as described in the text. CMTMR-labeled huRBC– mink-CD4 and calcein-loaded TF228 cells were cocultured at 377 for 4 hr. Images were
acquired as described in the text. (A –D) HIV-1 fusion after the transfer of huRBC components; (E –H) control cell pairs without huRBC transfer (HA0
not activated with trypsin, but the cells were treated at pH 5.1 as above). Positive fusion events indicated by orange– yellow color in the overlays.
FIG. 3. CMFDA-loaded target cells were cocultured with DiI-labeled TF228 cells for 2 hr at 377. Images were captured and analyzed as described
in the text. (A –D) K562-CD4 cells, (E–H) K562 cells.
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TABLE 1 TABLE 2
Pretreatment of RBC at 567 Does Not Affect Human Cell Lines with Pre-RBC Characteristics (K562-CD4)
Support HIV-1-Mediated Fusionthe Recovery of HIV-1 Fusion
% cell –cell Target cells % cell –cell fusion { SEM (n)a
RBC Pretreatment fusion {
components of RBC SEM (n)a CEM 63.2 { 9.4 (5)
K562-CD4 28.2 { 6.1 (8)
K562 1.3 { 1.0 (7)Human RBC None 20.2 { 3.4 (8)
Human RBC 567, 10 min 18.6 { 4.1 (7)
Nonhuman RBCb None 3.7 { 2.0 (4) a The values are expressed as the means { SEM (number of inde-
pendent experiments). The target cells were labeled with the fluores-None NA 3.1 { 1.8 (4)
cent probe CMFDA and cocultured with DiI-labeled TF228 cells for 2
hr at 377. Images were captured and analyzed and percentage of fusiona RBC components were transferred to mink-CD4 cells and the re-
sulting cell complexes were loaded with CMTMR and cocultured with was calculated as described in the text.
calcein-labeled TF228 cells for 4 hr at 377. Images were acquired (15–
20 cells per field) as described in the text. Values are expressed as
mean { SEM (number of fields). Similar results were obtained from at Although human erythrocyte membranes bear the ac-
least 8– 10 independent experiments.
cessory component(s) required for CD4-dependent fu-b Erythrocytes from goose and guinea pig were used as negative
sion (Ref. 17 and this report), it has been reported thatcontrols. Transfer of nonhuman RBC with or without preincubations at
567 for 10 min gave similar results. a CD4/ cell line with pre-RBC characteristics (K562-CD4)
is not susceptible to HIV-1 infectivity and syncytia forma-
tion with HIV-1 envelope glycoprotein-expressing cellsbe seen in Fig. 2, incubations in the absence (Fig. 2A)
(17). The fusion susceptibility of K562 cells was signifi-or presence (Fig. 2B) of WGA gave similar results. Pre-
cantly enhanced following expression of high levels oftreatment of huRBC at 567 prior to fusion with GP4F-
CD4 using vCB3 (H. Golding, unpublished observations).CD4/ cells mediated recovery of HIV-1 fusion which is
Using our fluorescence dye transfer method, we testedconsistent with the results in Table 1. These observations
the ability of K562-CD4 cells to fuse with TF228 cells.lead to the conclusion that HA-mediated huRBC compo-
The results are shown in Fig. 3 and Table 2. CMFDA-nents transfer results in CD4-dependent recovery of HIV-
loaded target cells cocultured with DiI-labeled TF2281 fusion.
cells for 2 hr at 377 were examined under bright field
(Figs. 3A and 3E) and epifluorescence (Figs. 3B and 3F,
fluorescein; Figs. 3C and 3G, rhodamine). Overlays of
fluorescein and rhodamine images are shown in Figs.
3D and 3H. Figure 3D shows that CMFDA-loaded K562-
CD4 cells cocultured with DiI-labeled TF228 cells be-
came positive for both fluorescent probes (indicated by
yellow color in the overlay, Fig. 3D).
K562 cells lacking CD4 did not show any overlap of
dyes (Fig. 3H and Table 2) under similar conditions. It is
also evident from the data in Table 2 that fusion efficiency
is much higher when a CD4-positive human lymphocyte
cell line (CEM) was used as target cells (63%) compared
to K562-CD4 cells (28% fusion).
Using a quantitative fluorescence video microscopic
assay we confirm here that human red blood cell mem-
branes provide the accessory factors required in addition
to CD4 to support HIV-1 fusion. These factors are insensi-
tive to heat treatment at 567 for 10 min, indicating these
molecules are either glycerolipids/glycolipids or heat-in-
sensitive proteins. The recovery of HIV-1 fusion is moreFIG. 2. HA-expressing mouse fibroblasts (GP4F) were infected with
efficient when huRBC components are transferred by HA-vCB3 to express human CD4. HuRBC were fused with GP4F cells as
described in the text. 5 mg/ml wheat germ agglutinin (WGA) was added mediated fusion than by PEG-mediated fusion. When
to promote binding between PK-treated RBC and GP4F cells. Fusion huRBC were transferred to mink-CD4 cells via PEG-medi-
of HA-modified GP4F cells with TF228 cells was monitored as de- ated fusion, subsequent fusion with TF228 cells occurred
scribed in the text. (A) huRBC, (B) huRBC/WGA, (C) PK-treated RBC,
only when huRBC were pretreated at 567 for 10 min (6%(D) 567-treated huRBC, (E) huRBC, GP4F cells without CD4 expression.
fusion yield). Heat treatment of huRBC is likely to disruptOpen bars, /human component transfer; hatched bars,0human com-
ponent transfer. the cytoskeletal elements, which allows more efficient
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